Clinicopathologic characteristics of HRAS-mutant head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Olazagasti, Coral
Rodriguez, Estelamari
Trabolsi, Asaad
Kareff, Samuel
Yin, Jun
Walker, Phillip
Wise-Draper, Trisha Michel
Chernock, Rebecca
Hanna, Glenn J.
Spetzler, David
Lopes, Gilberto
机构：
[1] Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami, Jackson Mem Hosp, Miami, FL USA
[4] Medstar Georgetown Univ Hosp, Washington, FL USA
[5] Caris Life Sci, Phoenix, AZ USA
[6] Univ Cincinnati Canc Ctr, Cincinnati, OH USA
[7] Washington Univ, St Louis, MO USA
[8] Dana Farber Canc Inst, Boston, MA USA
[9] Univ Miami Miller Sch Med, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6043
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
    Gilardi, Mara
    Wang, Zhiyong
    Proietto, Marco
    Chilla, Anastasia
    Calleja-Valera, Juan Luis
    Goto, Yusuke
    Vanoni, Marco
    Janes, Matthew R.
    Mikulski, Zbigniew
    Gualberto, Antonio
    Molinolo, Alfredo A.
    Ferrara, Napoleone
    Gutkind, J. Silvio
    Burrows, Francis
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (09) : 1784 - 1796
  • [2] Clinico-genetic profiling of HRAS mutant head and neck squamous cell carcinoma (HNSCC)
    Le, X.
    Marcelo, K.
    Coleman, N.
    Hopkins, J.
    Balsara, B.
    Leoni, M.
    Spelman, A. R.
    Hong, D. S.
    Albacker, L. A.
    Gillison, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S799 - S800
  • [3] Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
    Rampias, T.
    Hoxhallari, L.
    Avgeris, M.
    Kanaki, Z.
    Telios, D.
    Giotakis, E.
    Giotakis, I.
    Scorilas, A.
    Psyrri, A.
    Klinakis, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Clinicopathologic characteristics and mutational analysis of MYC amplified head and neck squamous cell carcinoma (HNSCC)
    Cyberski, Thomas
    Singh, Alka
    Lingen, Mark
    Pearson, Alexander
    Agrawal, Nishant
    Izumchenko, Evgeny
    Rosenberg, Ari
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Role of Harvey Ras (HRAS) mutations in head and neck squamous cell carcinoma (HNSCC)
    Endhardt, Katharina U.
    Khattri, Arun
    Keck, Michaela
    Braegelmann, Johannes
    Mahmutoglu, Derya
    Leung, Kelley
    El Dinall, Mohamed
    Rieke, Damian
    Cohen, Ezra
    Seiwert, Tanguy
    CANCER RESEARCH, 2012, 72
  • [6] Role of mutant HRAS in growth and drug sensitivity of head and neck squamous cell cancers (HNSCC).
    Javaid, Sehrish
    Waters, Andrew M.
    Nguyen, Victoria V.
    Der, Channing J.
    Cox, Adrienne D.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 72 - 72
  • [7] Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas
    Ho, A.
    Chau, N.
    Brana Garcia, I.
    Ferte, C.
    Even, C.
    Burrows, F.
    Kessler, L.
    Mishra, V.
    Magnuson, K.
    Scholz, C.
    Gualberto, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1367 - 1367
  • [8] Tipifarnib is highly active in HRAS-mutant HNSCC tumor models
    Gilardi, M.
    Wang, Z.
    Kessler, L.
    Janes, M.
    Chen, Y.
    Gualberto, A.
    Liu, Y.
    Gutkind, S.
    Burrows, F.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E137 - E137
  • [9] Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma
    Wang, Jiayu
    Al-Majid, Dana
    Brenner, J. Chad
    Smith, Joshua D.
    TARGETED ONCOLOGY, 2023, 18 (05) : 643 - 655
  • [10] Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma
    Jiayu Wang
    Dana Al-Majid
    J. Chad Brenner
    Joshua D. Smith
    Targeted Oncology, 2023, 18 : 643 - 655
12345